TD Cowen raises Ceribell stock price target on progress since IPO
TD Cowen raised its price target for Ceribell (CBLL) to $33 from $29, citing strong revenue growth and expanded market opportunities. The company reported $28.1M in Q2 revenue, up 33% YoY, and has beaten sales forecasts since its IPO. Multiple analysts have raised their price targets for Ceribell, reflecting positive sentiment and expectations for continued growth.
How this was made
The 30-second read
Why it matters
The earnings beat and analyst upgrades provide fresh data for traders to reassess valuation, especially given the company's rapid revenue growth and upcoming FDA submission for stroke detection.
Market read
First‑time Q2 earnings disclosure with strong growth, leading to multiple analyst upgrades and potential short‑term upside.
What to watch
Potential regulatory delays for the stroke indication and competition from larger neuro‑tech firms could temper growth.
Background
Ceribell, a point‑of‑care rapid EEG company, is nearing its two‑year IPO anniversary and has expanded its addressable market with new pediatric and stroke indications.
Ticker impact
Ceribell reported Q2 fiscal 2026 revenue of $28.1 million, a 33% year‑over‑year increase, prompting multiple analysts to raise price targets.
likely upward pressure as the market prices in stronger revenue growth and higher price targets.
Revenue beat and consistent growth have led three brokerages to lift targets, indicating fresh positive sentiment.
Market effects
Strengthens the neuro‑diagnostics sector as Ceribell's growth validates demand for point‑of‑care EEG solutions.
Positive for U.S. biotech investors focused on niche medical devices.
Limited to niche market; no broad macro impact.
Counterpoint
The stock may be overvalued given its high gross margin and modest absolute revenue; price targets could be premature.
Key entities
- companyCeribell
NASDAQ‑listed neuro‑diagnostics firm.
- analystTD Cowen
Raised price target to $33.
- analystCanaccord
Raised price target to $26.
- analystRaymond James
Raised price target to $29.
- analystBTIG
Raised price target to $30.